QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 6 May 2020Portfolio NewsNYC Health and Evidation Collaborate with the Icahn School of Medicine at Mount Sinai to Launch Study on COVID-19’s Impact on Mental Health
- 6 May 2020Portfolio NewsAVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
- 5 May 2020Portfolio NewsBicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab
- 4 May 2020Portfolio NewsAVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally
- 1 May 2020SV NewsHow the UK life sciences industry is rising to the challenge of Covid-19 by Kate Bingham
- 28 April 2020Portfolio NewsKarus Therapeutics Announces New Data from Phase I Cancer Trial at AACR
- 27 April 2020Portfolio NewsXilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer to lead XTX201 (tumor-selective IL-2) and XTX101 (tumor-Selective aCTLA-4) into the clinic while xilio continues to advance its tumor-selective cytokine pipeline
- 27 April 2020Portfolio NewsSutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
- 23 April 2020Portfolio NewsNitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related Diseases
- 21 April 2020Portfolio NewsAmwell Introduces New Telehealth Offering for Physician Practices
- 15 April 2020Portfolio NewsEvelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer - an industry veteran who brings deep experience in drug development from leadership roles at Regeneron and Vertex
- 14 April 2020Portfolio NewsCerevance Closes $45 Million Series B Financing - proceeds to fund a diverse pipeline of therapeutics acting on novel targets for brain diseases